Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Pharmakia Holding ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   3.7% 9.4% 3.6% 12.0% 10.6% 4.1% 13.5% 13.5%   Credit score (0-100)   53 26 51 19 22 49 17 17   Credit rating   BBB BB BBB BB BB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -5.7 -7.5 -7.5 -7.3 -9.1 -12.1 0.0 0.0   EBITDA   -5.7 -7.5 -7.5 -7.3 -9.1 -12.1 0.0 0.0   EBIT   -5.7 -7.5 -7.5 -7.3 -9.1 -12.1 0.0 0.0   Pre-tax profit (PTP)   311.6 -69.6 186.2 -178.5 -130.2 1,498.1 0.0 0.0   Net earnings   312.9 -67.8 187.9 -182.0 -130.2 1,503.2 0.0 0.0   Pre-tax profit without non-rec. items   312 -69.6 186 -178 -130 1,498 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   604 426 501 319 189 1,692 895 895   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 426 0.0 0.0   Balance sheet total (assets)   713 435 509 328 198 2,570 895 895   Net Debt   -194 -257 -144 -277 -20.8 231 -895 -895     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -5.7 -7.5 -7.5 -7.3 -9.1 -12.1 0.0 0.0   Gross profit growth   18.7% -32.2% 0.3% 3.3% -25.9% -32.0% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   713 435 509 328 198 2,570 895 895   Balance sheet change%   73.4% -39.0% 17.1% -35.6% -39.7% 1,199.4% -65.2% 0.0%   Added value   -5.7 -7.5 -7.5 -7.3 -9.1 -12.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   55.5% -11.2% 39.8% -42.2% -49.3% 109.3% 0.0% 0.0%   ROI %   62.3% -12.5% 40.5% -43.1% -51.1% 131.2% 0.0% 0.0%   ROE %   62.5% -13.2% 40.6% -44.4% -51.3% 159.9% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   84.8% 98.0% 98.4% 97.3% 95.4% 65.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   3,413.0% 3,419.2% 1,925.2% 3,823.5% 227.8% -1,914.9% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 25.2% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3,305.9% 0.0% 0.0% 0.0% 0.0% 6.8% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   2.7 40.2 28.0 31.3 8.8 0.8 0.0 0.0   Current Ratio   2.7 40.2 28.0 31.3 8.8 0.8 0.0 0.0   Cash and cash equivalent   194.2 257.3 144.4 277.4 20.8 194.7 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   184.0 342.4 222.6 268.5 70.3 -160.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0